These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9300234)

  • 1. Life-threatening hyperkalaemia caused by ACE inhibitor and diuretics.
    Jarman PR; Keheley AM; Mather HM
    Diabet Med; 1997 Sep; 14(9):808. PubMed ID: 9300234
    [No Abstract]   [Full Text] [Related]  

  • 2. Life-threatening hyperkalaemia caused by angiotensin-converting enzyme-inhibitor and diuretics.
    Odawara M; Asano M; Yamashita K
    Diabet Med; 1997 Feb; 14(2):169-70. PubMed ID: 9047098
    [No Abstract]   [Full Text] [Related]  

  • 3. Spironolactone + ace inhibitor or sartan: risk of hyperkalaemia.
    Prescrire Int; 2004 Apr; 13(70):58. PubMed ID: 15148978
    [No Abstract]   [Full Text] [Related]  

  • 4. [The 10-minute consultation. Accidental finding: hyperkalemia. Caution with analgesics and bananas].
    Lenz T
    MMW Fortschr Med; 2005 Jan; 147(4):59-60. PubMed ID: 15745346
    [No Abstract]   [Full Text] [Related]  

  • 5. Diabetes may be independent risk factor for hyperkalaemia.
    Jarman PR; Mather HM
    BMJ; 2003 Oct; 327(7418):812. PubMed ID: 14525902
    [No Abstract]   [Full Text] [Related]  

  • 6. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone.
    Berry C; McMurray J
    Am J Med; 2001 Nov; 111(7):587. PubMed ID: 11705445
    [No Abstract]   [Full Text] [Related]  

  • 7. [Malignant arrhythmias caused by hyperkalemia: a new area of drug-induced electrolyte abnormalities].
    Tomcsányi J; Somlói M; Arabadzisz H; Horváth L
    Orv Hetil; 2002 Mar; 143(13):663-6. PubMed ID: 11975043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Life threatening hyperkalaemia with diarrhoea during ACE inhibition.
    McGuigan J; Robertson S; Isles C
    Emerg Med J; 2005 Feb; 22(2):154-5. PubMed ID: 15662077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hyperkalemias].
    Radó J; Haris A
    Orv Hetil; 1999 Nov; 140(47):2611-8. PubMed ID: 10613044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.
    Ray K; Dorman S; Watson R
    J Hum Hypertens; 1999 Oct; 13(10):717-20. PubMed ID: 10516744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug-related hyperkalemia resulted from spironolactone and angiotensin converting enzyme inhibitors therapy].
    Dutka M; Dzielski T; Wojciechowska J; Heller L; Trybus M
    Pol Merkur Lekarski; 1999 Aug; 7(38):69-70. PubMed ID: 10522422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A patient with severe hyperkalaemia -- an emergency after RALES].
    Nürnberger J; Daul A; Philipp T
    Dtsch Med Wochenschr; 2005 Sep; 130(36):2008-11. PubMed ID: 16143930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing hypokalemia.
    Hollenberg NK
    Complicat Card Patient; 1987; 1(2):2, 32. PubMed ID: 11539714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients.
    Indermitte J; Burkolter S; Drewe J; Krähenbühl S; Hersberger KE
    Drug Saf; 2007; 30(1):71-80. PubMed ID: 17194172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe hyperkalaemia induced by trimethoprim in combination with an angiotensin-converting enzyme inhibitor in a patient with transplanted lungs.
    Bugge JF
    J Intern Med; 1996 Oct; 240(4):249-51. PubMed ID: 8918517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperkalaemia in diabetes: prevalence and associations.
    Jarman PR; Kehely AM; Mather HM
    Postgrad Med J; 1995 Sep; 71(839):551-2. PubMed ID: 7479468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.
    Schepkens H; Vanholder R; Billiouw JM; Lameire N
    Am J Med; 2001 Apr; 110(6):438-41. PubMed ID: 11331054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age.
    Dinsdale C; Wani M; Steward J; O'Mahony MS
    Age Ageing; 2005 Jul; 34(4):395-8. PubMed ID: 15955761
    [No Abstract]   [Full Text] [Related]  

  • 19. [Renal effect of treatment for heart failure].
    Rasmussen ZZ; Barfod T; Klit J
    Ugeskr Laeger; 2009 Feb; 171(9):718. PubMed ID: 19257999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug safety in patients with heart failure.
    Juurlink DN; Hansten PD
    Arch Intern Med; 2005 Jan; 165(1):118. PubMed ID: 15642888
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.